Joseph Jankovic | Academic Influence

Joseph Jankovic's AcademicInfluence.com Rankings

Joseph Jankovic

Medical

#140

World Rank

#217

Historical Rank

#70

USA Rank

Neurology

#6

World Rank

#20

Historical Rank

#3

USA Rank

medical Degrees

Download Badge

Medical

Joseph Jankovic's Degrees

Doctorate Medicine University of Belgrade

Why Is Joseph Jankovic Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joseph Jankovic is an American neurologist and professor at Baylor College of Medicine in Houston, Texas. He is the Distinguished Chair in Movement Disorders and founder and director of the Parkinson's Disease Center and Movement Disorders Clinic.

(See a Problem?)

Joseph Jankovic's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Parkinson’s disease: clinical features and diagnosis (2008) (4380)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
Phenomenology and classification of dystonia: A consensus update (2013) (1573)
Variable expression of Parkinson's disease (1990) (1167)
The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000) (921)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies (2019) (871)
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy (1996) (814)
Therapeutic uses of botulinum toxin. (1991) (803)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD (2003) (791)
Parkinson's Disease and Movement Disorders (1988) (773)
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. (2010) (575)
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. (2003) (538)
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale (2013) (534)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. (2009) (526)
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. (2008) (520)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial (2010) (490)
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations (2005) (485)
Functional decline in Parkinson disease. (2001) (420)
Resveratrol-Activated AMPK/SIRT1/Autophagy in Cellular Models of Parkinson's Disease (2011) (408)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache (2016) (388)
Mutations in NR4A2 associated with familial Parkinson disease (2003) (386)
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. (2006) (383)
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008) (380)
Botulinum toxin in clinical practice (2004) (374)
Parkinson disease subtypes. (2014) (372)
Exploring the relationship between Parkinson disease and restless legs syndrome. (2002) (354)
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. (1993) (347)
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. (1990) (341)
Therapy with botulinum toxin (1994) (340)
Tardive dystonia (1982) (339)
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (337)
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (337)
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial (2012) (335)
The heterogeneity of Parkinson's disease (1985) (334)
Age at onset in two common neurodegenerative diseases is genetically controlled. (2002) (332)
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia (2004) (332)
Long-term evaluation of deep brain stimulation of the thalamus. (2006) (329)
Freezing of gait in PD (2001) (328)
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression (2011) (320)
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. (1998) (316)
Long-term effects of tetrabenazine in hyperkinetic movement disorders (1997) (314)
Effects of visual and auditory cues on gait in individuals with Parkinson's disease (2004) (310)
Hemidystonia: a report of 22 patients and a review of the literature. (1985) (309)
Complete genomic screen in Parkinson disease: evidence for multiple genes. (2001) (302)
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination (1998) (300)
Accuracy of the Clinical Diagnosis of Corticobasal Degeneration (1997) (298)
Current approaches to the treatment of Parkinson’s disease (2008) (296)
Blepharospasm and orofacial‐cervical dystonia: Clinical and pharmacological findings in 100 patients (1983) (295)
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease (2005) (293)
Botulinum toxin injections for cervical dystonia (1990) (292)
The genetics of Parkinson disease (2018) (288)
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia (2003) (287)
Cervical dystonia (1991) (285)
Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture (2013) (280)
Dystonia and tremor induced by peripheral trauma: predisposing factors. (1988) (279)
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
Sensory aspects of movement disorders (2014) (276)
Safety of botulinum toxin type A: a systematic review and meta-analysis (2004) (271)
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. (1989) (270)
The impact of depressive symptoms in early Parkinson disease (2007) (270)
Restless legs syndrome (1996) (268)
Camptocormia: Pathogenesis, classification, and response to therapy (2005) (267)
Parkinson’s disease: etiopathogenesis and treatment (2020) (267)
Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. (1995) (264)
Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor (1998) (263)
Psychogenic Movement Disorders (2015) (263)
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. (2008) (261)
Contemporary assessment and pharmacotherapy of Tourette syndrome (2006) (257)
Essential tremor (1991) (252)
The role of FUS gene variants in neurodegenerative diseases (2014) (252)
Premonitory sensory phenomenon in Tourette's syndrome (2003) (252)
Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial (2005) (251)
Clinical correlates of vascular parkinsonism. (1999) (247)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. (2012) (231)
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia (1997) (231)
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. (2013) (226)
Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial (2015) (225)
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. (2003) (224)
Variability and validity of polymorphism association studies in Parkinson’s disease (2000) (223)
Treatment of hyperkinetic movement disorders (2009) (219)
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study (2005) (219)
Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. (2007) (218)
Decreased [18F]Spiperone Binding in Putamen in Idiopathic Focal Dystonia (1997) (215)
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. (2002) (215)
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. (2000) (215)
An Update on Tardive Dyskinesia: From Phenomenology to Treatment (2013) (211)
Freezing of gait in PD: Prospective assessment in the DATATOP cohort (2001) (211)
Tourette's syndrome. (2001) (211)
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) (2008) (209)
Treating severe bruxism with botulinum toxin. (2000) (208)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
Exploring the relationship between essential tremor and Parkinson's disease. (2007) (207)
Pallidotomy for generalized dystonia (1998) (207)
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia (2005) (206)
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy (2006) (206)
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (2007) (206)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. (1999) (206)
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement (2008) (205)
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
A randomized, double‐blind, placebo‐controlled study to evaluate botulinum toxin type A in essential hand tremor (1996) (202)
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. (1997) (200)
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. (1989) (199)
Criteria for the diagnosis of essential tremor. (2000) (196)
Botulinum toxin: Historical perspective and potential new indications (1997) (195)
Blepharospasm associated with brainstem lesions (1983) (195)
A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease (1994) (194)
Long‐term botulinum toxin efficacy, safety, and immunogenicity (2005) (194)
GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities (2007) (193)
Botulinum toxin A in patients with oromandibular dystonia (1999) (193)
Reduced Nurrl Expression Increases the Vulnerability of Mesencephalic Dopamine Neurons to MPTP‐Induced Injury (1999) (193)
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease (2007) (193)
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome (2006) (192)
Segmental myoclonus. Clinical and pharmacologic study. (1986) (191)
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (2019) (191)
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. (2001) (190)
Therapies in Parkinson's disease. (2012) (190)
Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms (2019) (189)
Nurr1 in Parkinson's disease and related disorders (2006) (188)
Treatment of Dystonia (2013) (188)
Phenomenology and classification of tics (1997) (187)
Botulinum toxin in the treatment of tics. (2000) (186)
Parkinson disease and the immune system — associations, mechanisms and therapeutics (2020) (182)
Tourette syndrome: Evolving concepts (2011) (181)
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay (2008) (181)
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. (2006) (179)
Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism (2001) (178)
Movement disorders in cerebrovascular disease (2013) (176)
Searching for a relationship between manganese and welding and Parkinson’s disease (2005) (175)
Delayed-onset progressive movement disorders after static brain lesions (1996) (175)
Dopa-responsive dystonia—clinical and genetic heterogeneity (2015) (174)
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment (2010) (172)
Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders (2007) (171)
Post‐traumatic movement disorders (1994) (171)
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease (2010) (171)
Daytime sleepiness and other sleep disorders in Parkinson’s disease (2001) (170)
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study (1982) (168)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial (2018) (165)
Peripherally induced oromandibular dystonia (1998) (165)
Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients (1983) (163)
Olanzapine treatment for dopaminergic‐induced hallucinations (2002) (163)
The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms (2011) (160)
A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome (2009) (160)
Preclinical biomarkers of Parkinson disease. (2011) (159)
A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics (2008) (158)
Association between essential tremor and Parkinson's disease (1985) (158)
Essential tremor: A heterogenous disorder (2002) (157)
Iron dysregulation in movement disorders (2012) (156)
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. (2005) (155)
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease (2007) (155)
The effect of deep brain stimulation on quality of life in movement disorders (2005) (155)
Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. (2019) (153)
Medical treatment of dystonia (2013) (153)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. (2016) (152)
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond (2013) (152)
The alien hand and related signs. (1992) (150)
Re-emergent tremor of Parkinson’s disease (1999) (150)
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden‐Spatz syndrome) and pantothenate kinase‐associated neurodegeneration (2004) (147)
Malignant Tourette syndrome (2007) (144)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
Identification of TMEM230 mutations in familial Parkinson’s disease (2016) (143)
Drug Insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide (2006) (141)
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. (1999) (140)
Apolipoprotein E controls the risk and age at onset of Parkinson disease (2004) (140)
Diffusion, spread, and migration of botulinum toxin (2013) (137)
Reliability of a new scale for essential tremor (2012) (136)
Movement disorders and AIDS (1987) (135)
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. (2010) (135)
Botulinum toxin: State of the art (2017) (135)
Potential Therapeutic Properties of Green Tea Polyphenols in Parkinson’s Disease (2003) (134)
Role of nitric oxide in rotenone‐induced nigro‐striatal injury (2003) (133)
Levodopa strengths and weaknesses (2002) (133)
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson’s disease (2002) (132)
Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. (2001) (132)
The association between Parkinson's disease and melanoma (2011) (131)
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. (2006) (131)
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. (2007) (131)
Treatment of Dystonia (2006) (130)
Natural History of Multiple System Atrophy in North America: A Prospective Cohort Study (2015) (129)
Topiramate in essential tremor (2006) (129)
Intrathecal baclofen for intractable axial dystonia (1991) (129)
Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. (1987) (128)
Stiff-person syndrome: insights into a complex autoimmune disorder (2014) (127)
Principles and practice of movement disorders (2011) (127)
Decreased NURR1 gene expression in patients with Parkinson's disease (2008) (127)
Head injury and posttraumatic movement disorders. (2002) (127)
Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators (2007) (126)
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (2019) (126)
Respiratory problems in neurologic movement disorders. (2010) (125)
Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial (2000) (125)
Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response (1998) (123)
Relationship between various clinical outcome assessments in patients with blepharospasm (2009) (123)
Polymorphism of NACP-Rep1 in Parkinson’s disease: An etiologic link with essential tremor? (2000) (123)
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. (2015) (123)
The spectrum of movement disorders in children with anti‐NMDA receptor encephalitis (2013) (123)
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008) (122)
Intrafamilial phenotypic variability of the DYT1 dystonia: From asymptomatic TOR1A gene carrier status to dystonic storm (2002) (122)
Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease (1989) (121)
Late‐onset Hallervorden‐Spatz disease presenting as familial parkinsonism (1985) (121)
Clinical gait and balance scale (GABS): validation and utilization (2004) (120)
Lesch‐nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters (1988) (120)
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease (2010) (119)
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA) (2013) (119)
Tardive syndromes and other drug-induced movement disorders. (1995) (119)
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia (2011) (119)
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. (1980) (117)
Focal task‐specific tremor and dystonia (1988) (117)
Pain in Parkinson's disease (2012) (117)
Tetrabenazine in the treatment of hyperkinetic movement disorders (2006) (116)
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders (2011) (116)
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location (2009) (116)
Tardive and idiopathic oromandibular dystonia: a clinical comparison (2000) (116)
Secondary paroxysmal dyskinesias (2002) (115)
Symptomatic treatment of Huntington disease (2008) (115)
Dystonia and parkinsonism. (2001) (115)
Multiple LRRK2 variants modulate risk of Parkinson disease: a chinese multicenter study (2010) (115)
Progressive supranuclear palsy and a multi‐infarct state (1987) (113)
Striatal deformities of the hand and foot in Parkinson's disease (2005) (112)
Neurodegenerative disease and iron storage in the brain (2004) (112)
Diagnosis and Management of Parkinson's Disease (2017) (111)
Clinical correlates of response to botulinum toxin injections. (1991) (110)
Botulinum toxin in the treatment of blepharospasm and hemifacial spasm (2007) (109)
Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. (2014) (109)
Update on blepharospasm (2008) (109)
Minocycline in Huntington's disease: A pilot study (2004) (108)
Safety of MRI in patients with implanted deep brain stimulation devices (2009) (107)
Essential tremor: clinical characteristics. (2000) (105)
Epigenetic mechanisms in Parkinson's disease (2015) (104)
Motor, Behavioral and Pharmacologic Findings in Tourette's Syndrome (1987) (104)
Glycoproteomics in neurodegenerative diseases. (2010) (103)
The relationship between essential tremor and Parkinson's disease. (2016) (102)
Genome-wide association study of Tourette Syndrome (2012) (102)
Dopamine depleters in the treatment of hyperkinetic movement disorders (2016) (102)
Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. (2007) (102)
Blinking and blepharospasm. Mechanism, diagnosis, and management. (1982) (102)
Mutations in NR4A2 associated with familial Parkinson disease (2003) (101)
Genetics of essential tremor. (2007) (101)
Occurrence of Tics in Asperger's Syndrome and Autistic Disorder (2000) (101)
Descriptive Epidemiology of Cervical Dystonia (2013) (101)
Low cancer rates among patients with Parkinson's disease (1985) (101)
Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects (1995) (101)
Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. (1999) (100)
Long-term prognosis of patients with psychogenic movement disorders. (2006) (100)
Blepharospasm: demographic and clinical survey of 250 patients. (1984) (100)
Basal Ganglia Neuronal Discharge in Primary and Secondary Dystonia in Patients Undergoing Pallidotomy (2003) (99)
Benefits and Risks of Pharmacological Treatments for Essential Tremor (2003) (99)
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice (2000) (99)
Deep Brain Stimulation for Tourette Syndrome: Target Selection (2012) (98)
Are Dopamine Receptor Agonists Neuroprotective in Parkinson’s Disease? (2001) (98)
Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome (2015) (98)
Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. (1996) (97)
Animal Models of Parkinson’s Disease: A Gateway to Therapeutics? (2013) (96)
Comparison of Thalamotomy and Pallidotomy for the Treatment of Dystonia (2001) (96)
The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. (2011) (96)
Psychogenic movement disorders in children (2008) (95)
Revisiting the relationship between essential tremor and Parkinson's disease (2011) (95)
Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk (2018) (94)
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. (2011) (94)
The therapeutic potential of cannabinoids for movement disorders (2015) (94)
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection (2000) (94)
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells (2010) (93)
Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease (2010) (93)
Outcome after stereotactic thalamotomy for dystonia and hemiballismus. (1995) (93)
Tourette syndrome. Phenomenology and classification of tics. (1997) (93)
Parkinsonism, movement disorders and genetics in frontotemporal dementia (2016) (93)
Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. (1992) (92)
Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. (2019) (92)
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies (1999) (92)
Disease-oriented approach to botulinum toxin use. (2008) (92)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
The clinical features of psychogenic movement disorders resembling tics (2013) (91)
Pathogenesis and pathophysiology of functional (psychogenic) movement disorders (2019) (90)
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families (2007) (90)
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections (1998) (89)
Movement disorders in autoimmune diseases (2012) (89)
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. (2002) (88)
Assessment of motor function after stereotactic pallidotomy (1998) (87)
Peripheral trauma and movement disorders: a systematic review of reported cases (2011) (87)
Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial (2005) (87)
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia (2008) (86)
Botulinum toxin therapy for cervical dystonia (2006) (86)
Bilateral pedunculopontine nuclei strokes presenting as freezing of gait (2008) (86)
Psychogenic movement disorders: diagnosis and management. (2004) (86)
CAG repeat size and clinical presentation in Huntington's disease (1994) (86)
Essential tremor quantification during activities of daily living. (2011) (85)
The VPS35 gene and Parkinson's disease (2013) (85)
The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells (2012) (84)
Cardiovascular and metabolic responses to upper- and lower-extremity exercise in men with idiopathic Parkinson's disease. (1996) (84)
Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation (2005) (84)
Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
Peripherally induced movement disorders. (2009) (83)
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia (2006) (83)
Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. (1988) (83)
Valproic acid‐mediated Hsp70 induction and anti‐apoptotic neuroprotection in SH‐SY5Y cells (2005) (82)
Hearing impairment in essential tremor (2003) (82)
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS (2013) (82)
Tardive dyskinesia and other movement disorders secondary to aripiprazole (2011) (82)
Globus pallidus deep brain stimulation in dystonia (2006) (82)
Tetrabenazine Treatment for Huntington's Disease-Associated Chorea (2002) (82)
Distinguishing psychogenic and essential tremor (2007) (82)
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. (2014) (82)
Bruxism and cranial-cervical dystonia: is there a relationship? (1999) (82)
Peripherally induced tremor and parkinsonism. (1995) (82)
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome (2006) (81)
Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk (2018) (81)
Immunogenicity Associated with Botulinum Toxin Treatment (2019) (81)
Paroxysmal kinesigenic dyskinesia and infantile convulsions (2000) (80)
Extrapyramidal involvement in Rett's syndrome (1990) (80)
Movement disorders induced by deep brain stimulation. (2016) (80)
Bilineal transmission in Tourette syndrome (1999) (80)
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia (2016) (79)
Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration (1999) (78)
Movement disorders in musicians (2008) (78)
Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson’s Disease (2015) (78)
Etiopathogenesis of Parkinson Disease: A New Beginning? (2009) (78)
Vascular progressive supranuclear palsy. (1994) (77)
A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder (1996) (77)
Progression of Parkinson disease: are we making progress in charting the course? (2005) (77)
Myorhythmia: Phenomenology, etiology, and treatment (2015) (77)
Iron chelation and neuroprotection in neurodegenerative diseases (2011) (76)
Treatment of cervical dystonia with botulinum toxin (2004) (76)
Tardive syndromes (2018) (76)
Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. (2014) (75)
Camptocormia, head drop and other bent spine syndromes: Heterogeneous etiology and pathogenesis of Parkinsonian deformities (2010) (75)
Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia (2013) (75)
Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. (2003) (74)
Autopsy‐proven Huntington's disease with 29 trinucleotide repeats (2007) (74)
Multiple system atrophy: the putative causative role of environmental toxins. (1999) (74)
A variant in the HS1-BP3 gene is associated with familial essential tremor (2005) (73)
Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
Dopamine agonists in Parkinson’s disease (2003) (73)
Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. (1985) (73)
Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. (2011) (73)
Deep Brain Stimulation Hardware Complications in Patients with Movement Disorders: Risk Factors and Clinical Correlations (2012) (72)
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome (2013) (72)
Concepts and Methods in Chronic Thalamic Stimulation for Treatment of Tremor: Technique and Application (2001) (72)
Dystonia in musicians. (1989) (72)
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. (2007) (72)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Neurologic Approach to Drug‐Induced Movement Disorders: A Study of 125 Patients (1990) (71)
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. (2013) (71)
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. (1997) (70)
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial (2011) (70)
Migraine headache in patients with Tourette syndrome. (2003) (70)
Movement disorders in multiple sclerosis and other demyelinating diseases (2013) (70)
Genome-wide association study in essential tremor identifies three new loci (2016) (70)
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor (2010) (69)
Genetic testing in Parkinson disease: promises and pitfalls. (2006) (69)
Botulinum toxin in movement disorders (1994) (69)
Alleviating manoeuvres (sensory tricks) in cervical dystonia (2014) (69)
Classification, diagnosis, and etiology of gait disorders. (2001) (69)
An update on new and unique uses of botulinum toxin in movement disorders (2018) (68)
Rett syndrome: Controlled study of an oral opiate antagonist, naltrexone (1994) (68)
Advances in the Pharmacological Management of Huntington’s Disease (2010) (68)
Treatment of dystonia. (2007) (68)
Propofol-induced dyskinesias in Parkinson's disease. (1996) (68)
Psychogenic Tremor: Long-Term Outcome (2006) (68)
Symptomatic and functional outcome of surgical treatment of cervical dystonia (1997) (67)
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. (2008) (67)
Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease (2008) (67)
Severe dystonia and myoglobinuria (1982) (67)
Treatable inherited rare movement disorders (2018) (66)
Tardive stereotypy and other movement disorders in tardive dyskinesias (1993) (66)
Tourettism and dystonia after subcortical stroke (2002) (66)
Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. (2008) (66)
Restless legs syndrome: clinical presentation diagnosis and treatment. (2015) (66)
Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy (2005) (66)
Botulinum toxin injection for congenital muscular torticollis presenting in children and adults (2006) (65)
Essential tremor course and disability: A clinicopathologic study of 20 cases (2004) (65)
Phenotypic features of Huntington's disease‐like 2 (2003) (65)
Dystonia in spinocerebellar ataxia type 6 (2002) (65)
Runner's dystonia (2006) (64)
ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients (2017) (64)
Parkinson's Disease & Movement Disorders (2002) (64)
Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH‐SY5Y cells (2015) (64)
Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease (2014) (63)
Deutetrabenazine in Tics Associated with Tourette Syndrome (2016) (63)
Use of botulinum toxin type A in the treatment of cervical dystonia. (2000) (63)
Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. (2005) (62)
Treatment of dysautonomia associated with Parkinson's disease. (2009) (62)
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. (2000) (62)
Whole-Exome Sequencing in Familial Parkinson Disease. (2016) (62)
Premutation alleles associated with Parkinson disease and essential tremor. (2004) (62)
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration (2008) (62)
Outcome after Stereotactic Thalamotomy for Dystonia and Hemiballismus (1995) (62)
Clozapine use in diffuse Lewy body disease. (1993) (62)
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. (2003) (62)
Dystonia: medical therapy and botulinum toxin. (2004) (61)
Autoimmune and paraneoplastic movement disorders: An update (2018) (61)
Blepharospasm with basal ganglia lesions. (1986) (61)
Continuous in-home monitoring of essential tremor. (2014) (61)
Deprenyl in attention deficit associated with Tourette's syndrome. (1993) (61)
Complications and limitations of drug therapy for Parkinson's disease. (2000) (61)
Anosmia and Ageusia in Parkinson's Disease. (2017) (61)
Psychiatric associations of adult-onset focal dystonia phenotypes (2017) (60)
A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study (1997) (60)
Alcohol in essential tremor and other movement disorders (2010) (60)
Overnight Switch From Oral Dopaminergic Agonists to Transdermal Rotigotine Patch in Subjects With Parkinson Disease (2007) (59)
Exploring the Correlates of Intermediate CAG Repeats in Huntington Disease (2011) (59)
Minocycline and Other Tetracycline Derivatives: A Neuroprotective Strategy in Parkinson's Disease and Huntington's Disease (2003) (59)
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis (1997) (59)
Changes in cognitive‐emotional and physiological symptoms of depression following STN‐DBS for the treatment of Parkinson’s disease (2012) (59)
Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2015) (59)
Diagnosis and classification of tics and Tourette syndrome. (1992) (59)
Hereditary motor–sensory neuropathy and movement disorders (1993) (58)
Genetic analysis of the GABRA1 gene in patients with essential tremor (2006) (58)
Essential tremor-plus: a controversial new concept (2019) (58)
Neuro-ophthalmic findings in progressive supranuclear palsy. (1992) (58)
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy) (2014) (58)
Diagnosis and treatment of psychogenic parkinsonism (2011) (58)
Exercise performance in those having Parkinson's disease and healthy normals. (1999) (58)
Potential outcome measures and trial design issues for multiple system atrophy (2007) (58)
Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics (2019) (57)
Emerging therapies for Parkinson's disease. (2012) (57)
Tardive oculogyric crises (1989) (57)
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. (1995) (57)
Essential Tremor Among Children (2004) (57)
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease (2007) (57)
Differential diagnosis and etiology of tics. (2001) (56)
Weight gain following unilateral pallidotomy in Parkinson's disease (2000) (56)
Are Parkinson disease patients protected from some but not all cancers? (2007) (56)
Asian over-representation among patients with hemifacial spasm compared to patients with cranial–cervical dystonia (2010) (56)
Essential Tremor and Parkinson’s Disease: Exploring the Relationship (2019) (56)
Benign coital cephalalgia. Differential diagnosis and treatment. (1981) (55)
Tourette's syndrome in adults (2010) (55)
Secondary tics and tourettism (2005) (54)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
Shoulder pain: a presenting symptom of Parkinson disease. (2008) (54)
Surgery for Parkinson's Disease and Movement Disorders (2001) (54)
An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy (2000) (53)
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia (2016) (53)
Neurologic presentation of Wilson disease without Kayser-Fleischer rings (1996) (53)
Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amid the COVID-19 Pandemic: A Cross-sectional Study. (2021) (53)
Psychogenic hemifacial spasm. (2001) (53)
THE OTHER BABINSKI SIGN IN HEMIFACIAL SPASM (2007) (53)
F-box only protein 7 gene in parkinsonian-pyramidal disease. (2012) (53)
Relationship of aging to Parkinson's disease. (1987) (52)
Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. (2017) (52)
Long‐term efficacy and safety of fluphenazine in patients with Tourette syndrome (2014) (52)
A case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm. (2000) (52)
Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson’s disease (2000) (52)
The coexistence of tics and dystonia. (1991) (52)
Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls (2011) (52)
The nosology of tardive syndromes (2018) (52)
Parkinsonism‐plus syndromes (1989) (52)
Erratum: Mutations in NR4A2 associated with familial Parkinson disease (Nature Genetics (2003) 33 (85-89)) (2003) (51)
Short‐term effects of tetrabenazine on chorea associated with Huntington's disease (2007) (51)
Diagnosis and treatment of complications related to deep brain stimulation hardware (2011) (51)
Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration (2010) (51)
Acquired hepatocerebral degeneration (2009) (51)
Chorea associated with Huntington's disease: To treat or not to treat? (2014) (51)
Tourette syndrome: pieces of the puzzle. (2001) (51)
The genetics of Tourette syndrome (2012) (51)
Recent Advances in Understanding and Managing Tourette Syndrome (2016) (51)
Genetic analysis of LRRK2 mutations in patients with Parkinson disease (2006) (51)
Paroxysmal kinesigenic dyskinesias. (2003) (51)
Analysis of CYP2D6 genotype and response to tetrabenazine (2013) (51)
Needle EMG guidance is rarely required (2001) (51)
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease (2016) (50)
Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. (1996) (50)
Reflexive and volitional saccades: Biomarkers of Huntington disease severity and progression (2012) (50)
Is History of Depression a Contraindication to Treatment With Tetrabenazine? (2006) (50)
The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor (2007) (50)
Secondary tics and tourettism. (2005) (49)
Classification of paroxysmal dyskinesias and ataxias. (2002) (49)
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. (2012) (49)
Dystonia and dyskinesia. (1997) (49)
Outcome measurement in functional neurological disorder: a systematic review and recommendations (2020) (49)
Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. (1999) (49)
Botulinum Toxin in Movement Disorders: An Update (2021) (49)
A Pilot Study of a Cognitive–Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease (2015) (49)
Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families (2001) (48)
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
An update on the treatment of Parkinson's disease. (2006) (48)
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine (2014) (48)
9p monosomy in a patient with Gilles de la Tourette's syndrome (1991) (47)
Atomoxetine for freezing of gait in Parkinson disease (2009) (47)
Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia (2019) (47)
Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson’s disease (2018) (47)
Peptidoglycan recognition protein genes and risk of Parkinson's disease (2014) (47)
Onabotulinum toxin-A injections for sleep bruxism (2018) (47)
Progressive supranuclear palsy. Clinical and pharmacologic update. (1984) (47)
Medical therapy and botulinum toxin in dystonia. (1998) (47)
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm (2013) (47)
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. (2019) (47)
Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. (1988) (47)
Tardive dyskinesia and withdrawal emergent syndrome in children (2010) (46)
Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy (1983) (46)
Young-onset Parkinson's disease: Its unique features and their impact on quality of life. (2019) (46)
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. (2006) (46)
Long‐term study of pergolide in Parkinson's disease (1985) (46)
The inv dup(l5) syndrome: A clinically recognizable syndrome with altered behavior, mental retardation, and epilepsy (1997) (46)
Long‐term deep brain stimulation for essential tremor: 12‐year clinicopathologic follow‐up (2010) (46)
Psychogenic Tremor: A Video Guide to Its Distinguishing Features (2014) (45)
Motor symptoms in Parkinson's disease. (2007) (45)
Familial essential tremor in 4 kindreds. Prospects for genetic mapping. (1997) (45)
Transcription factor PITX3 gene in Parkinson's disease (2011) (45)
Huntington's disease: How intermediate are intermediate repeat lengths? (2012) (45)
Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection (2005) (44)
Respiratory dyskinesia in Parkinson's disease (1986) (44)
Huntington disease: A quarter century of progress since the gene discovery (2019) (44)
Applause sign in parkinsonian disorders and Huntington's disease (2008) (44)
New and emerging medical therapies in Parkinson’s disease (2016) (44)
Essential tremor and parkinson's disease (1989) (44)
Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy (1998) (43)
Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease (2000) (43)
Pharmacological treatment of Tourette syndrome (2014) (43)
The course of depressive symptoms in early Parkinson's disease (2009) (43)
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease (2009) (43)
Drug-induced and other orofacial-cervical dyskinesias. (1981) (43)
Motor overflow and mirror dystonia. (2009) (43)
Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease (2005) (43)
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments (2020) (42)
Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT (2012) (42)
Secondary causes of paroxysmal dyskinesia. (2002) (41)
Silvicultural Strategies for Conversion (2004) (41)
Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations (1989) (41)
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated (2014) (41)
CROSS REACTION OF TETANUS AND BOTULINUM NEUROTOXINS A AND B AND THE BOOSTING EFFECT OF BOTULINUM NEUROTOXINS A AND B ON A PRIMARY ANTI-TETANUS ANTIBODY RESPONSE (2002) (41)
Modafinil for fatigue in MS : A randomized placebo- controlled double-blind study. Authors' reply (2005) (41)
Efficacy and tolerability of pregabalin in essential tremor: A randomized, double-blind, placebo-controlled, crossover trial (2009) (40)
Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo‐controlled crossover study (2018) (40)
(−)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition (1997) (40)
Movement disorders in Friedreich's ataxia (2003) (40)
Emerging drugs in Tourette syndrome (2005) (39)
Yips and other movement disorders in golfers (2013) (39)
Hemiballism and metastatic brain tumor (1984) (39)
Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. (2001) (39)
Focal hand dystonia, mirror dystonia and motor overflow (2008) (39)
Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population (2007) (39)
Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. (2000) (38)
Glabellar and palmomental reflexes in parkinsonian disorders (2004) (38)
Consensus for the measurement of the camptocormia angle in the standing patient. (2018) (38)
Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice (2005) (37)
Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. (1990) (37)
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia (2003) (37)
Metoclopramide‐induced tardive dyskinesia in an infant (2005) (37)
Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain (2009) (37)
Pathophysiology and Clinical Assessment of Parkinsonian Symptoms and Signs (2003) (37)
Treatment options for chorea (2018) (37)
Familial hemifacial spasm. (1990) (37)
Movement disorders in catatonia (2014) (37)
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors (2018) (36)
Childhood Stiff-Person Syndrome Improved with Rituximab (2012) (36)
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. (2008) (36)
Psychogenic movement disorders and other conversion disorders (2011) (36)
Comprar Parkinson's Disease and Movement Disorders, 6ª Ed. | Joseph Jankovic | 9781608311767 | Lippincott Williams & Wilkins (2015) (36)
Clinical and genetic features of cervical dystonia in a large multicenter cohort (2016) (36)
Are psychogenic non-epileptic seizures just another symptom of conversion disorder? (2017) (36)
Cranial-cervical dyskinesias: an overview. (1988) (36)
Use of botulinum toxin in the treatment of hand dystonia. (1993) (36)
Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. (2000) (36)
Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. (1999) (36)
Gender Differences in Functional Movement Disorders (2020) (35)
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. (2005) (35)
Haplotype analysis of the ETM2 locus in familial essential tremor (2003) (35)
MDMA and Parkinsonism. (2003) (35)
HS1‐BP3 gene variant is common in familial essential tremor (2006) (35)
Botulinum Toxin for the Treatment of Hand Tremor (2018) (35)
Flu-like symptoms following botulinum toxin therapy. (2011) (35)
Amplitude fluctuations in essential tremor. (2012) (35)
Pathogenesis‐targeted therapeutic strategies in Parkinson's disease (2018) (35)
The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. (1998) (35)
Movement Disorders: Diagnosis and Assessment (2008) (34)
G2019S mutation in the leucine‐rich repeat kinase 2 gene is not associated with multiple system atrophy (2007) (34)
Low Body Weight in Parkinson's Disease (1992) (34)
Switching from pergolide to pramipexole in patients with Parkinson's disease (2001) (34)
LINGO1 variants in essential tremor and Parkinson’s disease (2012) (34)
Therapeutic Developments for Tics and Myoclonus (2015) (34)
Autosomal dominant mitochondrial membrane protein‐associated neurodegeneration (MPAN) (2019) (33)
Practical management of dystonia. (1984) (33)
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose‐Escalation Multicenter Study (2018) (33)
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea (2017) (33)
Movement Disorders in Childhood (2015) (32)
Parkinson's disease and movement disorders: moving forward (2008) (32)
Tics associated with other disorders. (2006) (32)
Gait disorders. (2015) (32)
Neuroprotection in Parkinson disease. (2003) (32)
Evidence-Based Review of Patient-Reported Outcomes With Botulinum Toxin Type A (2004) (32)
Media hype: Patient and scientific perspectives on misleading medical news (2017) (32)
The EIF4G1 gene and Parkinson's disease (2015) (32)
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine (2016) (32)
Neurohistopathological Findings at the Electrode–Tissue Interface in Long‐Term Deep Brain Stimulation: Systematic Literature Review, Case Report, and Assessment of Stimulation Threshold Safety (2014) (32)
Slowing Parkinson's disease progression: recent dopamine agonist trials. (2004) (32)
Levodopa-induced dyskinesias treated by pallidotomy (1999) (31)
Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. (1988) (31)
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. (2011) (31)
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. (2012) (31)
Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm (2009) (31)
Research Priorities in Limb and Task-Specific Dystonias (2017) (31)
An Open-Label Pilot Study of Levetiracetam for Essential Tremor (2004) (31)
Globus pallidus internus neuronal activity: a comparative study of linear and non-linear features in patients with dystonia or Parkinson’s disease (2016) (31)
Genetic mouse models of essential tremor: are they essential? (2005) (31)
Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States (2010) (30)
Genetics and molecular biology of brain calcification (2015) (30)
Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. (2001) (30)
Tourette's syndrome and the law. (2006) (30)
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. (2008) (30)
NKX2-1-Related Disorders (2016) (30)
The future of research in Parkinson disease. (2014) (30)
Choosing dopamine agonists in Parkinson's disease. (2001) (30)
Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. (2011) (30)
Dermatological manifestations of Tourette syndrome and obsessive-compulsive disorder. (1998) (29)
Rapid Communication Muscle Mitochondrial ATP Production in Progressive Supranuclear Palsy (1994) (29)
Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. (2014) (29)
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. (2007) (29)
The α-synuclein gene is not a major risk factor in familial Parkinson disease (1999) (29)
Pallidal surgery for the treatment of Parkinson's disease and movement disorders (1998) (29)
Parallel double-blind study of pergolide in Parkinson's disease. (1987) (29)
Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. (2009) (29)
Clinimetric testing of the comprehensive cervical dystonia rating scale (2016) (28)
Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. (2019) (28)
Speech and voice disorders in patients with psychogenic movement disorders (2015) (28)
Tetrabenazine in the treatment of Tourette syndrome (2007) (28)
Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. (1995) (28)
Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism (2003) (28)
The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. (2001) (28)
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. (2014) (28)
Adrenal medullary autografts in patients with Parkinson's disease. (1989) (28)
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders (2015) (28)
Zolpidem improves tardive dyskinesia and akathisia (2013) (28)
Tetrabenazine in the treatment of hyperkinetic movement disorders. (1983) (28)
Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy (2006) (27)
Decreased [18F]spiperone binding in putamen in dystonia. (1998) (27)
Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study (1998) (27)
Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders (1994) (27)
Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. (1998) (27)
Parkinson's disease after COVID-19 (2021) (27)
A variant in the HS1-BP3 gene is associated with familial essential tremor (2005) (27)
NEUTRALIZING ANTIBODIES IN DYSTONIC PATIENTS WHO STILL RESPOND WELL TO BOTULINUM TOXIN TYPE A (2008) (27)
Botulinum Toxin for the Treatment of Tremor and Tics (2016) (26)
Movement disorders in 2016: Progress in Parkinson disease and other movement disorders (2017) (26)
Paroxysmal movement disorders. (2015) (26)
Examination of the SGCE gene in Tourette syndrome patients with obsessive–compulsive disorder (2004) (26)
Progress in research on Tourette syndrome. (2014) (26)
Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease (2012) (26)
The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor (2006) (26)
Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families (2008) (26)
Whipple's disease of the central nervous system in AIDS. (1986) (26)
Re-emergence of surgery for dystonia (1998) (26)
Coexistent tardive dyskinesia and parkinsonism. (1987) (26)
Treatment options for Parkinson's disease (2002) (26)
Botulinum Toxin Type A in the Management of Oromandibular Dystonia and Bruxism (2003) (25)
Arteriovenous malformation presenting as hemidystonia (1986) (25)
Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. (2009) (25)
Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor (2004) (25)
Comprar Principles and Practice of Movement Disorders, 2nd Edition | Mark Hallett MD | 9781437723694 | Saunders (2011) (25)
Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry (2015) (25)
Genetic movement disorders in patients of Jewish ancestry. (2014) (25)
Psychogenic (Functional) Movement Disorders. (2019) (25)
Subthalamic deep brain stimulation in patients with a previous pallidotomy (2006) (24)
Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon? (2019) (24)
Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed? (2012) (24)
Distinguishing features of psychogenic (functional) versus organic hemifacial spasm (2017) (24)
Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG33 repeat length in the Huntington's disease gene (2011) (24)
Treatment options for Parkinson's disease. (2002) (24)
Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? (2008) (24)
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE) (2011) (24)
Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis (2007) (24)
Dopamine transporter imaging in essential tremor with and without parkinsonian features (2014) (24)
A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration (2012) (24)
SPG11 Mutations Associated With a Complex Phenotype Resembling Dopa‐Responsive Dystonia (2015) (23)
Psychogenic chorea associated with family history of Huntington disease (2010) (23)
Dystonia & tremor: A cross-sectional study of the dystonia coalition cohort. (2020) (23)
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo (2008) (23)
Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients (2010) (23)
GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients (2009) (23)
Prin & Prac of Movement Disorders (2007) (23)
Substantia nigra lesions in viral encephalitis (2003) (23)
Meige's Syndrome (1980) (23)
Head tremor at disease onset: an ataxic phenotype of cervical dystonia (2019) (23)
“Psychogenic” versus “functional” movement disorders? That is the question (2014) (23)
Progress toward an integrated understanding of Parkinson’s disease (2017) (23)
Genetic Convergence of Parkinson’s Disease and Lysosomal Storage Disorders (2014) (23)
Mutations in the Novel Protein PRRT2 Cause Infantile Convulsions with Paroxysmal Kinesigenic Dyskinesia (2012) (23)
Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington’s and Other Diseases (2013) (23)
Parkinson's disease therapy: treatment of early and late disease. (2001) (23)
Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. (2012) (22)
Rett syndrome: qualitative and quantitative differentiation from autism. (1988) (22)
Clinical and Pharmacologic Findings in 21 Patients (2016) (22)
Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease (2011) (22)
Epidemiology and Management of Essential Tremor in Children (2009) (22)
Clinical phenotype in carriers of intermediate alleles in the huntingtin gene (2019) (21)
Placebo‐controlled study of mesulergine in Parkinson's disease (1985) (21)
4: Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008 (2009) (21)
Apraclonidine in the treatment of ptosis (2017) (21)
Placebo-induced conversion reaction: a neurobehavioral and EEG study of hysterical aphasia, seizure, and coma. (1983) (21)
Botulinum toxin for the treatment of tremor. (2019) (21)
Botulinum A toxin in the treatment of blepharospasm. (1988) (21)
Dopaminergic Properties and Experimental Anti-Parkinsonian Effects of IPX750 in Rodent Models of Parkinson Disease (2004) (21)
Parkinson's disease in monozygotic twins (1986) (21)
Tremor Syndromes: An Updated Review (2021) (21)
Selegiline orally disintegrating tablet in the treatment of Parkinsons disease (2006) (21)
Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. (2007) (20)
Surgical treatment of levodopa-induced dyskinesias. (1999) (20)
Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? (1987) (20)
Apraxia of lid opening. (1995) (20)
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis (2006) (20)
Hemiparkinsonism-hemiatrophy syndrome (2007) (20)
Treatment of tics associated with Tourette syndrome (2020) (20)
Treatment of advanced Parkinson’s disease (2006) (19)
Palatal myoclonus: An unusual presentation (2005) (19)
Recent Advances in the Management of Tics (1986) (19)
Hemidystonia‐hemiatrophy syndrome (2009) (19)
Contemporary assessment and pharmacotherapy of Tourette syndrome (2006) (19)
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia (2013) (18)
Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment (2011) (18)
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. (2012) (18)
Dystonia in corticobasal degeneration. (2000) (18)
Laterality and symptom association in Parkinson's disease. (1985) (18)
Real-World Experience With VMAT2 Inhibitors (2019) (18)
Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. (1997) (18)
Rett Syndrome: Qualitative and Quantitative Differentiation from Autism (1988) (18)
Immunologic treatment of Parkinson's disease. (2018) (18)
G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients (2005) (18)
TARDIVE DYSTONIA AND INAPPROPRIATE USE OF NEUROLEPTIC DRUGS (1982) (18)
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. (2014) (18)
How Do I Examine for Re‐Emergent Tremor? (2016) (17)
Botulinum toxin in dermatology – beyond wrinkles and sweat (2006) (17)
Human T-cell responses to botulinum neurotoxin Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients (2011) (17)
Alexia without agraphia in Creutzfeldt–Jakob disease (2007) (17)
Essential tremor (2021) (17)
Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. (1999) (17)
Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson’s disease (2003) (17)
Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism (2005) (17)
The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. (1999) (17)
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. (2001) (17)
Focal dystonia: The role of botulinum toxin (2001) (17)
Quality of life in isolated dystonia: non-motor manifestations matter (2021) (17)
Tics and Tourette's syndrome (1997) (17)
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia (2013) (17)
The association of Tourette syndrome and dopa‐responsive dystonia (2011) (17)
Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson’s Disease in a Movement Disorders Clinic (2021) (17)
Progressive supranuclear palsy (1985) (16)
Hand, foot, and spine deformities in parkinsonian disorders (2019) (16)
Candidate locus for chorea and tic disorders at 15q? (2007) (16)
Examination of the MASH1 gene in patients with Parkinson's disease. (2010) (16)
Mobility, mood and site of care impact health related quality of life in Parkinson's disease. (2014) (16)
Hemiparkinsonism and hemiatrophy (1988) (16)
New and emerging therapies for Parkinson disease. (1999) (16)
Management of Motor Side Effects of Chronic Levodopa Therapy (1982) (16)
Methods of H-Reflex Evaluation in the Early Stages of Parkinson’s Disease (2002) (16)
Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms (2018) (16)
Bradley´s Neurology in Clinical Practice, 6th Edition (2012) (16)
Dystonia and other deformities in Parkinson's disease (2005) (16)
Botulinum toxin for the treatment of cervical dystonia (2001) (16)
Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins (2013) (16)
Functional gait disorders, clinical phenomenology, and classification (2019) (16)
Functional (psychogenic) stereotypies (2017) (16)
Pathophysiology and clinical assessment (2013) (15)
Tics in Other Neurological Disorders (2004) (15)
Psychogenic (functional) parkinsonism. (2016) (15)
Is Benign Hereditary Chorea Really Benign? Brain‐Lung‐Thyroid Syndrome Caused by NKX2‐1 Mutations (2018) (15)
Familial spastic paraparesis and deafness. A new x-linked neurodegenerative disorder. (1986) (15)
Post-traumatic movement disorders: effect of the legal system on outcome. (1998) (15)
Clinical Assessment of the Effect of Tetrabenazine on Functional Scales in Huntington Disease: A Pilot Open Label Study (2012) (15)
Hereditary chin tremor in Parkinson's disease (2007) (15)
Thalamic surgery for movement disorders. (1997) (15)
Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease (2012) (15)
Vagus nerve stimulation for essential tremor (2003) (15)
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease (2020) (15)
Radiofrequency lesioning through deep brain stimulation electrodes: A pilot study of lesion geometry and temperature characteristics (2013) (14)
Essential tremor and PD (1993) (14)
Parkinson's disease tremors and serotonin. (2018) (14)
Tardive myoclonus. (1987) (14)
Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications (2013) (14)
Designing Clinical Trials for Dystonia (2013) (14)
Parkinson disease: Exenatide – a drug for diabetes and Parkinson disease? (2017) (14)
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B (2011) (14)
Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease (2020) (14)
What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease? (1998) (14)
Hyperkinetic movement disorders in congenital disorders of glycosylation (2019) (14)
Respiratory disorders associated with dystonia (2012) (14)
Alcohol dehydrogenase polymorphism and Parkinson's disease (2001) (13)
Adult onset tics after peripheral injury. (2008) (13)
Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. (1995) (13)
Tuberous sclerosis and chorea (1983) (13)
Upper facial chorea in Huntington disease (2014) (13)
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans (2011) (13)
Soleus H-reflex measures in patients with focal and generalized dystonia (2003) (13)
Essential tremor: genetic update (2019) (13)
Psychogenic Ophthalmologic Movement Disorders. (2016) (13)
Cervical dystonia and substance abuse (2018) (13)
Deutetrabenazine for the treatment of Huntington’s chorea (2018) (13)
Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study (2018) (13)
Psychogenic myoclonus (1993) (13)
Treatment of blepharospasm with apraclonidine (2017) (13)
Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? (2019) (13)
Long-term use of dopamine agonists in Parkinson's disease. (1985) (13)
Surgical treatment of Parkinson's disease. (1996) (13)
Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes (2020) (13)
LINGO1 rs9652490 variant in Parkinson disease patients (2011) (12)
Clinical use of botulinum neurotoxins. (1995) (12)
Predictors of alcohol responsiveness in dystonia (2018) (12)
Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. (2001) (12)
Parkinson's disease: recent advances in therapy. (1988) (12)
Complete genomic screen in Parkinson Disease (2001) (12)
Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm (2014) (12)
Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. (1990) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Parkinson's disease and skin. (2020) (12)
Advances in Neurology: Facial Dyskinesias (1989) (11)
Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease (2007) (11)
Motor–phonic tic mimicking essential palatal myoclonus (2009) (11)
Current concepts in Parkinson's disease and other movement disorders. (2012) (11)
Beyond tics: movement disorders in patients with Tourette syndrome (2021) (11)
Worldwide barriers to genetic testing for movement disorders (2021) (11)
Understanding falls in progressive supranuclear palsy. (2017) (11)
Postural Directionality and Head Tremor in Cervical Dystonia (2020) (11)
Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease (2010) (11)
Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early‐onset primary dystonia (2013) (11)
Recent advances in understanding and treatment of Parkinson’s disease (2020) (10)
Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study (2019) (10)
Role of botulinum toxin in the treatment of cervical dystonia. (2008) (10)
Bolivian kindred with combined spinocerebellar ataxia types 2 and 10 (2015) (10)
Hypertension and progressive supranuclear palsy. (2019) (10)
Tardive gait (2008) (10)
Hereditary myoclonus and progressive muscular atrophy: a new syndrome. (1978) (10)
Distinguishing Clinical Features of Hyperkinetic Disorders (2012) (10)
Leg stereotypy syndrome: phenomenology and prevalence (2018) (10)
H-Reflex Recovery Curves Differentiate Essential Tremor, Parkinson’s Disease, and the Combination of Essential Tremor and Parkinson’s Disease (2002) (10)
Haemorrhagic complications of multiple sclerosis. (1980) (10)
Motor disorders in patients with human immunodeficiency virus infection. (1989) (10)
Chorea and ballism. (1992) (10)
Mozart's movements and behaviour: a case of Tourette's syndrome? (2007) (10)
Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. (2003) (10)
Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. (1996) (10)
Leg stereotypy disorder (2015) (10)
Parkinson's disease. A half century of progress. (2001) (10)
Comprar Psychogenic Movement Disorders And Other Conversion Disorders + Dvd | Mark Hallett | 9781107007345 | Cambridge University Press (2011) (10)
Current approaches in the treatment of Parkinson's disease. (1993) (9)
The Role of TMEM230 Gene in Parkinson’s Disease (2018) (9)
Letters to the editor (1990) (9)
Clinical overview and phenomenology of movement disorders (2021) (9)
Hemidystonia secondary to carotid artery gunshot injury (1997) (9)
Oromandibular Dystonia: A Clinical Examination of 2,020 Cases (2021) (9)
Psychogenic myoclonus (1993) (9)
PALLIDOTOMY AND GENERALIZED DYSTONIA. AUTHORS' REPLY (1999) (9)
Sleep and Tic Disorders (2013) (9)
Diagnostic criteria for blepharospasm: A multicenter international study. (2021) (9)
Gene dosage analysis of α‐synuclein (SNCA) in patients with Parkinson's disease (2006) (9)
Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies (2021) (9)
Mutation screening of the HTR2B gene in patients with Tourette syndrome (2012) (9)
Education Research: Patient telephone calls in a movement disorders center (2009) (9)
Exercise and Parkinson's disease (1996) (9)
Association of Essential Tremor With Novel Risk Loci (2022) (9)
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome (2021) (8)
Genetic study of an American family with DYT3 dystonia (lubag) (2008) (8)
Erratum: Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease (Human Molecular Genetics (2003) vol. 12 (3259-3267)) (2004) (8)
L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency? (1981) (8)
Lower body (vascular) parkinsonism. (1990) (8)
Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: A possible complication of chronic hypoxia and carbon monoxide toxicity? (2004) (8)
Neuroacanthocytosis syndrome and choreoacanthocytosis (Levine‐Critchley syndrome) (1985) (8)
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome (2021) (8)
Dystonia and Tremor (2021) (8)
Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients (2016) (7)
Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. (2006) (7)
Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome (2007) (7)
Basal ganglia neuronal discharge in primary and secondary dystonia. (2004) (7)
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. (2021) (7)
Occupation and Risk of Parkinsonism (2016) (7)
diagnosis Parkinson's disease: clinical features and (2008) (7)
Effect of levodopa treatment for parkinsonism in welders: A double-blind study. Authors' reply (2004) (7)
Counseling At-Risk Parkinson’s Disease Cohorts: Integrating Emerging Evidence (2017) (7)
“Complex” dystonia is not a category in the new 2013 consensus classification (2016) (7)
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
Inherited Metabolic Disorders with Associated Movement Abnormalities (2016) (7)
Proton magnetic resonance spectroscopic studies of hypertrophied muscle. Effect of botulinum toxin treatment. (1991) (7)
Examiner manoeuvres ‘sensory tricks’ in functional (psychogenic) movement disorders (2016) (7)
Clinical Diagnosis of Vascular Parkinsonism and Nondegenerative Atypical Parkinsonian Disorders (2005) (6)
Clinical aspects of progressive supranuclear palsy. (2008) (6)
Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease (2018) (6)
Orofacial and other self-mutilations. (1988) (6)
Botulinum Toxins: Transformation of a Toxin into a Treatment (2005) (6)
Movement Disorder Surgery: Patient Selection and Evaluation of Surgical Results (2000) (6)
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. (2021) (6)
Drug-induced dystonia in neuronal ceroid-lipofuscinosis. (1986) (6)
The etiopathogenetic and pathophysiological spectrum of parkinsonism (2021) (6)
Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease (2020) (6)
It's tricky: Rating alleviating maneuvers in cervical dystonia (2020) (6)
Essential Tremor (2006) (6)
Diagnosis of Neurological Disease (2008) (6)
Treatment of Tardive Dyskinesia. (2020) (6)
Author Correction: Dystonia (2018) (6)
Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. (2020) (6)
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule (2018) (6)
ESSENTIAL TREMOR. AUTHOR'S REPLY (1992) (6)
Reply to: Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome (2011) (6)
The Relationship Between Parkinson’s Disease and Other Movement Disorders (1989) (6)
Comprar Bradley - Neurology in Clinical Practice E-dition (Book + Website Package) 2 vols. | Joseph Jankovic | 9780750675253 | Butterworth Heinemann (2007) (6)
Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions (2015) (5)
Advances in Neurology, Volume 49, Facial Dyskinesias (1988) (5)
An introduction to dyskinesia--the clinical spectrum. (2011) (5)
Unique properties of botulinum toxins. (2009) (5)
Patient Selection for Surgery for Parkinson’s Disease (2009) (5)
Deep Brain Stimulation of the Subthalamic Nucleus for Peripherally Induced Parkinsonism (2014) (5)
Occupation and Risk of Parkinsonism A Multicenter (2009) (5)
Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome (2021) (5)
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia11Edited by Hans E. Grossniklaus, MD (2003) (5)
A Multi‐center Genome‐wide Association Study of Cervical Dystonia (2021) (5)
Effects of pallidotomy on gait and balance. (2001) (5)
Parkinson’s Disease: Diagnosis, Motor Symptoms and Non-Motor Features (2013) (5)
Head tremor and pain in cervical dystonia (2021) (5)
Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. (2019) (5)
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. (2016) (5)
Neuro-ophthalmology of movement disorders (2018) (5)
Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma (2018) (5)
Does Added Objective Tremor Monitoring Improve Clinical Outcomes in Essential Tremor Treatment? (2018) (4)
Chapter 5 – Current concepts on the etiology and pathogenesis of Parkinson disease (2007) (4)
Comprar Botulinum Toxin. Therapeutic Clinical Practice and Science (Expert Consult - Online and Print) | Joseph Jankovic | 9781416049289 | Saunders (2009) (4)
Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001) (2015) (4)
Head tremor in cervical dystonia: Quantifying severity with computer vision (2022) (4)
A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia (2021) (4)
Experience, competency, and education: Graduating neurology residents' experience with tPA. Authors' reply (2002) (4)
Clinical and Demographic Characteristics of Upper Limb Dystonia (2020) (4)
[Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. (1997) (4)
Postural Control in Essential Temor (1996) (4)
Quality of Life and Cost Effectiveness of Deep Brain Stimulation in Movement Disorders (2008) (4)
Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease (2010) (4)
Botulinum Neurotoxin Injections in Childhood Opisthotonus (2021) (4)
Surgical Treatments of Dystonia (2008) (4)
Poster 49: Efficacy and Safety of NT 201 (Botulinum Neurotoxin Free From Complexing Proteins) in Cervical Dystonia (2010) (4)
Treatment of dystonia and tics (2019) (4)
Self-injurious behavior in Tourette syndrome (2021) (4)
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies (2022) (4)
Erratum: (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition (Neuroscience Letters PII: S0304394097001705) (1997) (4)
Basic and therapeutic aspects of neurotonins (2004) (4)
Rett Syndrome: Motor and Behavioral Differentiation from Autism (1987) (4)
Available treatment options for dystonia (2017) (4)
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions (2022) (4)
Botulinum Toxin Treatment in Parkinson’s Disease and Atypical Parkinsonian Disorders (2018) (3)
Animal models of Parkinson's disease (2013) (3)
Stereotactic Neurosurgery for Dystonia (2000) (3)
Parkinsonism and tremor syndromes (2021) (3)
Introduction to dystonia (2012) (3)
Chorea, Athetosis, and Ballism (2016) (3)
The Clinical Value of Patient Home Videos in Movement Disorders (2021) (3)
What is It? Difficult to Pigeon Hole Tremor: a Clinical–Pathological Study of a Man with Jaw Tremor (2013) (3)
Early‐stage Parkinson's disease: To treat or not to treat (1994) (3)
FP50-TH-06 Efficacy and safety of NT 201 (Xeomin®, botulinum neurotoxin free from complexing proteins) in cervical dystonia (2009) (3)
Chapter 34 – Movement Disorders (2007) (3)
Long-term treatment of blepharospasm and cervical dystonia: Incobotulinum /INS;toxin /INS;A is well tolerated when injected at flexible intervals based on patient needs (2013) (3)
Functional (psychogenic) saccadic oscillations and oculogyric crises (2016) (3)
Reply from the Author (1995) (3)
Natural course and limitations of levodopa therapy (1992) (3)
Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? (2021) (3)
Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study (2018) (3)
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal (2021) (3)
New version of the UPDRS: Development methods and working document for field testing (2005) (3)
Myoglobinuric renal failure in Huntington's chorea (1986) (3)
Genome Sequencing in the Parkinson Disease Clinic (2021) (3)
Theories on the etiology and pathogenesis of Parkinson's disease (1992) (3)
Movement disorders. (1993) (3)
Evidence for Multiple Genes (2001) (3)
Examination of the MSX1 gene in patients with Parkinson’s disease (2009) (3)
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. (2020) (3)
Current Trends in the Treatment of Parkinson's Disease (1992) (3)
Botulinum neurotoxins as therapeutics (2014) (3)
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491 (2020) (3)
Tourette Syndrome and Driving (2021) (3)
Manual of Botulinum Toxin Therapy: Botulinum toxin in tic disorders and essential hand and head tremor (2009) (3)
Lesch-Nyhan Syndrome: A Study of Motor Behavior and CSF Monoamine Turnover (1987) (3)
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects (2021) (3)
Chapter 24 – Restless Legs Syndrome and Peripheral Movement Disorders (2007) (3)
CHAPTER 11 – Basal Ganglia and Movement Disorders (2010) (3)
Chapter 8 – Botulinum Neurotoxin Treatment of Cranial-Cervical Dystonia (2009) (3)
Faculty Opinions recommendation of Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. (2014) (3)
SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease (2010) (3)
The clinical phenomenology and correlations of oculogyric tics (2022) (3)
Integrated Sequencing & Array Comparative Genomic Hybridization in Familial Parkinson’s Disease (2019) (2)
Camptocormia : Pathogenesis, classification, and response to therapy. Authors' reply (2006) (2)
The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases? (2022) (2)
The Long-Term Efficacy and Safety of Fluphenazine in Patients with Tourette Syndrome (P02.057) (2013) (2)
Movement disorders. (2015) (2)
Parkinson's disease: from basic research to treatment. Advances in Neurology, Vol. 60: H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno (Eds.) (Raven Press, New York, 1993, 784 p., Price US $150.00 (distributed in Japan exclusively by Igaku-Shoin)) (1993) (2)
Prospects for Genetic Mapping (2016) (2)
A peptide‐based immunoassay for antibodies against botulinum neurotoxin A (2007) (2)
Peripheral movement disorders (2021) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiology (2022) (2)
Chapter 128 – Primary and Secondary Generalized Dystonias (2003) (2)
The Putative Causative Role of Environmental Toxins (2016) (2)
Parkinsonism and dystonia associated with adalimumab (2011) (2)
Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. (2008) (2)
Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study (2022) (2)
Medical treatment of blepharospasm (2018) (2)
Huntington Disease and Other Genetic Choreas (2012) (2)
Basal Ganglia Anatomy, Biochemistry, and Physiology (2016) (2)
Adrenal‐to‐caudate transplantation (1990) (2)
Diagnostic Evaluation of Children with Movement Disorders (2016) (2)
Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. (2017) (2)
Hemiballism-Hemichorea-Reply (1990) (2)
Update on the management of motor complications in Parkinson's disease (2005) (2)
Movement Disorders in Neurologic and Systemic Disease: List of contributors (2014) (2)
Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. (2010) (2)
Cervical dystonia: an update on therapeutics (2019) (2)
Movement disorders in childhood metabolic diseases (2014) (2)
Hold that pose: capturing cervical dystonia's head deviation severity from video (2022) (2)
Medical treatment of the motor features of Parkinson disease (2021) (2)
A PHASE 2, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF DAXIBOTULINUMTOXINA FOR INJECTION (RT002) IN ISOLATED CERVICAL DYSTONIA (P3.021) (2016) (2)
Gene-Environment Interactions in Progressive Supranuclear Palsy (2021) (2)
Botulinum toxin in the clinical management of cervical dystonia (2000) (2)
FP50-TH-05 Efficacy and safety of NT 201 (Xeomin®, botulinum neurotoxin type A free from complexing proteins) for the treatment of blepharospasm: results of a double-blind, placebo-controlled, randomized, multi-center trial (2009) (2)
Reply (1984) (2)
F1000Prime recommendation of Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. (2016) (1)
Chapter 12 – Myoclonus (2016) (1)
Parkinson’s Disease: Medical and Surgical Treatment (2013) (1)
Reply to: “Toward a Personalized Approach to Parkinson's Cell Therapy” (2020) (1)
Chapter 14 – Ataxia (2016) (1)
Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population (2017) (1)
Spinocerebellar ataxia types 2 and 10: more than a coincidental association? (2012) (1)
Tourette Syndrome: The Neurology of a Tic: From the Point of View of the Scientist (2002) (1)
Faculty Opinions recommendation of Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS. (2020) (1)
Acknowledgement of Technological Limitations While Moving Literature Forward (2010) (1)
Comprar Bradley´s Neurology in Clinical Practice, 6th Edition | Joseph Jankovic | 9781437704341 | Saunders (2012) (1)
4.36 A Randomized, Double-Blind, Placebo-Controlled Study of the D1 Receptor Antagonist Ecopipam for Children and Adolescents With Tourette's Disorder (2017) (1)
Exploring the role of botulinum toxin in critical care (2021) (1)
Letters to the editor (1995) (1)
Predictors of onabotulinumtoxina response in patients with cervical dystonia (2016) (1)
Reader response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy (2019) (1)
Nonmotor problems in Parkinson disease (2021) (1)
Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis (2021) (1)
Migraine and Tourette syndrome. Authors' reply (2004) (1)
Antiglutamic Acid Decarboxylase 65 Antibody-Associated Hemiataxia. (2021) (1)
Flu-Like and Systemic Symptoms Following Treatment with Botulinum Toxins (P01.230) (2012) (1)
Pathophysiology and molecular pathology of dystonia and tics. in: Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment (2012) (1)
Movement Disorders in Neurologic and Systemic Disease: Movement disorders of autoimmune origin (2014) (1)
Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (1)
Faculty Opinions recommendation of Novel subcellular localization for α-synuclein: possible functional consequences. (2017) (1)
Movements that Occur in Sleep (2016) (1)
Long-Term Efficacy, Safety, and Side Effect Profile of Botulinum Toxin Injections in Dystonia – A 20-Year Follow-Up (P07.197) (2013) (1)
Posttraumatic Tremor and Other Posttraumatic Movement Disorders (2013) (1)
Essential Tremor ( ET ) Botulinum toxin treatment in tremors BTX treatment of limb tremor (2013) (1)
Movement Disorders in Neurologic and Systemic Disease: Principles of management in movement disorders (2014) (1)
Dystonia-Spasticity in a Patient with a Novel SLC25A12 Mutation (P2.138) (2015) (1)
Chapter 33 - Psychogenic Movement Disorders (2010) (1)
PSYCHOGENIC MYOCLONUS. AUTHORS' REPLY (1994) (1)
Clinical Gait and Balance Scale (2019) (1)
152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents (2020) (1)
Statin-related musculoskeletal pain in Parkinson's disease. (2017) (1)
5 – Transient and Developmental Movement Disorders in Children (2016) (1)
Depressed Mood and Memory Impairment Before and After Unilateral Posteroventral Pallidotomy in Parkinson’s Disease (2008) (1)
Faculty Opinions recommendation of Nilotinib effects on safety, tolerability, and potential biomarkers in parkinson disease: A phase 2 randomized clinical trial. (2020) (1)
Chapter 20 – Cerebral Palsy (2016) (1)
Systemic Disease and Movement Disorders (2013) (1)
Features of Cervical Dystonia Following Peripheral Trauma (2004) (1)
Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment, with Desktop Edition (2012) (1)
Deep Brain Stimulation for Cervical Dystonia (2007) (1)
Laboratory Investigations in Diagnosis and Management of Neurological Disease (2008) (1)
Neurological Clinical Examination: A Concise Guide (2012) (1)
Natural history study of MSA in North America: A prospective cohort study (2015) (1)
Friedreich’s Ataxia Presenting With Childhood Onset Progressive Dystonia and Spasticity (2012) (1)
Zolpidem Improves Tardive Dyskinesia with and without Akathisia (P07.205) (2013) (1)
Faculty Opinions recommendation of Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. (2018) (1)
Tourette Syndrome: The Neurology of a Tic (2002) (1)
Medication-Induced Movement Disorders: L-Dopa dyskinesias (2015) (1)
Postural Stability and Control in Persons With Parkinsonʼs Disease on and off Levodopa (1996) (1)
Faculty of 1000 evaluation for Defects in trafficking bridge Parkinson's disease pathology and genetics. (2017) (1)
Deep brain stimulation. Authors' reply (2005) (1)
Chapter 11 – Dystonia (2016) (1)
Outcomes of week-24 completers and subjects who had follow-up beyond week 24 after a single treatment of daxibotulinumtoxinA for injection (RT002): Results of a phase 2, open-label (Level II), dose-escalating study in isolated cervical dystonia (2018) (1)
Overview of the Medical Treatment of the Non‐Motor and Non‐Dopaminergic Features of Parkinson's Disease (2011) (1)
P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) (2009) (1)
Safety and efficacy of DaxibotulinumtoxinA for injection (RT002) in cervical dystonia (CD): Results of a phase 2, dose escalating study (2018) (1)
Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study (P3.016) (2016) (0)
Ask the Experts: Differentiating Parkinson’s disease from other parkinsonian disorders (2013) (0)
Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin–naive subjects: Results from a phase 3 study (2018) (0)
4.14 A PILOT STUDY OF SD-809 (DEUTETRABENAZINE) IN TICS ASSOCIATED WITH TOURETTE'S DISORDER (2016) (0)
Faculty Opinions recommendation of Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end? (2020) (0)
Faculty Opinions recommendation of Changing views of the pathophysiology of Parkinsonism. (2019) (0)
Faculty Opinions recommendation of Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies. (2016) (0)
Movement disorders following non-metal intoxications (2014) (0)
Faculty Opinions recommendation of How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. (2020) (0)
[Table, GeneReview Scope]. (2016) (0)
Rationale for a vaccine against herpes zoster and postherpetic neuralgia in olden adults (2006) (0)
Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. (2020) (0)
Analysis of the Behavioral Features Conferred by the Intermediate Allele for Huntington Disease in the Prospective Huntington at Risk Observational Study (PHAROS) (PL01.003) (2012) (0)
Preoperative Magnetic Resonance Imaging and Clinical Outcome After Unilateral Posteroventral Pallidotomy for Parkinson's Disease: 777 (1997) (0)
Psychogenic myoclonus (1994) (0)
6 - Tics and Tourette Syndrome (2010) (0)
Long-Term Safety and Efficacy of Tetrabenazine in the Treatment of Chorea Associated with Huntington's Disease (P06.034) (2012) (0)
Faculty Opinions recommendation of Cell therapy for Parkinson's disease: Why it doesn't work every time. (2019) (0)
Erratum: Movement Disorders from the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache (Headache (2016) 56:1 (156)) (2016) (0)
Faculty Opinions recommendation of Exercise for falls prevention in Parkinson disease: a randomized controlled trial. (2015) (0)
Faculty Opinions recommendation of Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. (2019) (0)
220 MAXIMUM EXERCISE PERFORMANCE IN INDIVIDUALS WITH PARKINSON??S DISEASE AND HEALTHY INDIVIDUALS (1993) (0)
Reply (2001) (0)
IncobotulinumtoxinA (Xeomin(R)) Is Well Tolerated for the Treatment of Blepharospasm When Injected According to Patient Needs (PD4.010) (2012) (0)
Faculty Opinions recommendation of Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. (2018) (0)
Neuroprotection in Hungtington's disease [1] (multiple letters) (2003) (0)
Effects of Posteroventral Pallidotomy on Static and Dynamic Balance in Patients With Parkinsonʼs Disease (1996) (0)
Faculty Opinions recommendation of The future of stem cell therapies for Parkinson disease. (2020) (0)
Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins (2013) (0)
Faculty Opinions recommendation of PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. (2017) (0)
Reply (1986) (0)
Faculty Opinions recommendation of Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease. (2017) (0)
Hyperkinetic Disorders Hyperkinetic Movement Disorders (2012) (0)
Letters to the Editor (1997) (0)
Faculty Opinions recommendation of A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. (2020) (0)
Respiratory complications of movement disorders (2014) (0)
Movement Disorders in Golfers (P02.070) (2013) (0)
Faculty Opinions recommendation of β2-adrenoreceptor medications and risk of Parkinson disease. (2020) (0)
XCiDaBLE: A Phase 4, Observational, Prospective Trial Evaluating Xeomin (IncobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States - Preliminary Baseline Disease Severity and Quality of Life Data (P01.240) (2012) (0)
Poster 507 Evaluation of Pain Relief in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2014) (0)
Genetic Convergence of Parkinson’s Disease and Lysosomal Storage Disorders (2014) (0)
Faculty Opinions recommendation of White matter changes and the development of motor phenotypes in de novo Parkinson's Disease. (2016) (0)
Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders (2021) (0)
Faculty Opinions recommendation of Challenges of modifying disease progression in prediagnostic Parkinson's disease. (2016) (0)
Treatment Outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (P7.069) (2014) (0)
12. Tics and Tourette Syndrome (2012) (0)
Chapter 8 – Motor Stereotypies (2016) (0)
Faculty Opinions recommendation of Immunotherapy in Parkinson's disease: Current status and future directions. (2019) (0)
Botulinum Neurotoxins as a Therapeutic (2021) (0)
Animal Models of Parkinson’s Disease: A Gateway to Therapeutics? (2013) (0)
Potential new uses of botulinum toxin injections in movement disorders (2016) (0)
Faculty Opinions recommendation of Use of botulinum toxin in Parkinson's disease. (2018) (0)
Genome-Wide Association Study of Gilles de la Tourette Syndrome (2012) (0)
Chapter 7 – Tics and Tourette Syndrome (2016) (0)
Faculty Opinions recommendation of Using smartphones and machine learning to quantify parkinson disease severity: the mobile parkinson disease score. (2018) (0)
A Pilot Study of SD-809 (Deutetrabenazine) in Tics Associated With Tourette's Disorder (2016) (0)
Task‐specific dystonias (1989) (0)
Chapter 18 – Movement Disorders in Autoimmune Diseases (2016) (0)
Surgical treatment of Parkinson disease and other movement disorders (2021) (0)
FP41-TH-01 Nurr1 and Pitx3 are risk factors for Parkinson's disease (2009) (0)
Huntington disease: Intermediate CAG repeats (2019) (0)
Orthostatic tremor (1991) (0)
Faculty Opinions recommendation of Spinal cord stimulation therapy for gait dysfunction in advanced parkinson's disease patients. (2018) (0)
Reply: Dystonia after severe head injuries (2014) (0)
Faculty of 1000 evaluation for Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. (2018) (0)
Letters to the editor (0)
Manual of Botulinum Toxin Therapy: The use of botulinum neurotoxin in tic disorders and essential hand and head tremor (2014) (0)
SUNCT responding to botulinum toxin (P3.049) (2015) (0)
Essential tremor (1992) (0)
Faculty Opinions recommendation of Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). (2018) (0)
Treatment of Movement Disorders. (2020) (0)
Faculty Opinions recommendation of Post hoc analysis of the Exenatide-PD trial-Factors that predict response. (2020) (0)
641 Accuracy of the clinical diagnosis of pick's disease (1996) (0)
Faculty Opinions recommendation of Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. (2013) (0)
Cerebellar Anatomy, Biochemistry, Physiology, and Plasticity (2016) (0)
Faculty Opinions recommendation of Colonic bacterial composition in Parkinson's disease. (2017) (0)
Table 1. [Molecular Genetic Testing Used in NKX2-1-Related Disorders]. (2016) (0)
Neurobiology of Disease (2012) (0)
Malignant Phonic Tics (2013) (0)
Faculty Opinions recommendation of Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. (2020) (0)
The Impact of Cervical Dystonia on Work Productivity: An Analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (P4.324) (2015) (0)
Reply from the Authors (1990) (0)
111. Long-term effects of botulinum toxin injections (2015) (0)
Faculty Opinions recommendation of Membrane remodeling and mechanics: Experiments and simulations of α-Synuclein. (2017) (0)
Faculty Opinions recommendation of The genetic architecture of Parkinson's disease. (2020) (0)
Reply: Autopsy‐proven Huntington's disease with 29 trinucleotide repeats (2008) (0)
Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: Results from a Phase III study (2021) (0)
Cranial–Cervical Dystonia (2009) (0)
A Pilot Study of SD-809 (Deutetrabenazine) in Tics Associated with Tourette Syndrome (P1.046) (2016) (0)
Poster 40 Cervical Dystonia Patient Registry for Observation of Botox Efficacy (CD PROBE): Interim Results of Pain‐related Outcomes (2011) (0)
Reply to the comments from Dr. Martinez-Martin (2004) (0)
Etiology and pathogenesis of Parkinson disease (2021) (0)
Chapter 13 – Tremor (2016) (0)
Progress in research on Tourett e syndrome (2014) (0)
Faculty Opinions recommendation of Cannabinoids for tourette's syndrome. (2016) (0)
Faculty Opinions recommendation of Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease. (2019) (0)
Movement Disorders in Neurologic and Systemic Disease: Phenomenology, classification, and diagnostic approach to patients with movement disorders (2014) (0)
Parkinson's disease slide library (1996) (0)
Tics and Tourette Syndrome: Phenomenology (2015) (0)
Faculty of 1000 evaluation for The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease. (2017) (0)
Comprar Bradley's Neurology In Clinical Practice (Online And Print) | Joseph Jankovic | 9781437704341 | Saunders (2012) (0)
Faculty Opinions recommendation of Dystonia and Parkinson's disease: What is the relationship? (2019) (0)
Movement Disorders After Traumatic Brain Injury (2012) (0)
Movement Disorders in Neurologic and Systemic Disease: Preface (2014) (0)
Faculty Opinions recommendation of Parkinson disease. (2020) (0)
Faculty Opinions recommendation of Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: A randomized clinical trial. (2017) (0)
Faculty Opinions recommendation of Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease. (2015) (0)
Functional (Psychogenic) Movement Disorders (2016) (0)
P2.141 Rasagiline provides symptomatic beneflt in early Parkinson's disease (PD) (2009) (0)
Faculty Opinions recommendation of Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. (2013) (0)
Treatment of Dopa-Responsive Dystonia (2019) (0)
TWO NOVELS ADDRESS CHALLENGES OF LIVING WITH TOURETTE SYNDROME (2001) (0)
Internet dyskinesias in Parkinson’s disease (2008) (0)
Faculty Opinions recommendation of Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. (2016) (0)
Metoclopramide, an Increasingly Recognized Cause (2008) (0)
Treatment of palatal myoclonus with sumatriptan. (1997) (0)
Short communication Alexia without agraphia in Creutzfeldt-Jakob disease (2007) (0)
Poster 50: Efficacy and Safety of NT 201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) for the Treatment of Blepharospasm: Results of a Double‐blind, Placebo‐controlled, Randomized, Multicenter Trial (2010) (0)
Comprar Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment, with Desktop Edition | Joseph Jankovic, MD | 9781444333527 | Wiley (2012) (0)
Continuous Home Monitoring of Essential Tremor Using Motion Sensors (P05.035) (2013) (0)
A New X-linked Neurodegenerative Disorder (2016) (0)
12. Movement Disorders (2014) (0)
Faculty Opinions recommendation of Chronic Use of β-Blockers and the Risk of Parkinson's Disease. (2020) (0)
Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Interim results of physician- and patient-reported outcomes (2013) (0)
Poster 102: CD‐PROBE (Cervical Dystonia Patient Registry for Observation of Botox Efficacy)— A Multicenter, Observational Study of OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients—Baseline Data and Interim Patient Reported Outcome (2010) (0)
Faculty of 1000 evaluation for Genetics of Parkinson disease. (2018) (0)
Faculty of 1000 evaluation for Intracellular dynamics of synucleins: "here, there and everywhere". (2017) (0)
RELIABILITY OF CARDIORESPIRATORY AND PHYSICAL PERFORMANCE MEASURES IN MALES AND FEMALES HAVING IDIOPATHIC PARKINSON'S DISEASE 855 (1996) (0)
Substance abuse in cervical dystonia (2017) (0)
Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Baseline Demographic and Clinical Characteristics (2013) (0)
Movement disorders. Preface. (2009) (0)
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson disease heterogeneity (2020) (0)
Basal Ganglia Disorders (2017) (0)
Faculty Opinions recommendation of Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). (2015) (0)
Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine (2020) (0)
Reply from the Authors (1996) (0)
Cervical dystonia and substance abuse (P5.061) (2018) (0)
Faculty Opinions recommendation of Protein transmission in neurodegenerative disease. (2020) (0)
Books Received (2001) (0)
Thealien handandrelated signs (1992) (0)
Faculty Opinions recommendation of Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. (2014) (0)
Reader response: The nature of postural tremor in Parkinson disease (2018) (0)
20 – Clinical aspects and treatment of cranial movement disorders (1990) (0)
Chapter 16 – Hereditary Spastic Paraplegia (2016) (0)
DELAYED-ONSET DYSKINESIA. AUTHOR'S REPLY (1996) (0)
Clinical and Imaging Data in Essential Tremor with Parkinsonian Features (P06.085) (2011) (0)
Clinical Uses of Botulinum Toxins: Botulinum toxin: primary and secondary resistance (2007) (0)
Faculty Opinions recommendation of Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. (2018) (0)
Faculty Opinions recommendation of Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study. (2015) (0)
2.300 SAFETY DATA IN A RANDOMIZED CONTROLLED TRIAL OF CONSTANT CURRENT DBS VERSUS LEAD PLACEMENT ALONE FOR PARKINSON'S DISEASE MOTOR FLUCTUATIONS (2012) (0)
Faculty Opinions recommendation of Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort. (2019) (0)
Management of Neurological Disease (2008) (0)
Phantom sensations (1986) (0)
Tics and Tourette syndrome (2021) (0)
Concomitant Use of Antidepressants and Neuroleptics with Tetrabenazine during Treatment of Huntington's Disease (HD) (P06.039) (2012) (0)
Childhood dystonia. (1993) (0)
Contents Vol. 20, 2012 (2012) (0)
Neuroprotection in Hungtington's Disease: RESPONSE FROM THE AUTHORS (2003) (0)
Metastatic hemiballism again (1984) (0)
Faculty of 1000 evaluation for Gene therapy for parkinson's disease, an update. (2018) (0)
A validation of a self-administered screening test for Parkinson's disease (2020) (0)
Is exercise beneficial for Parkinsonʼs disease patients (2005) (0)
Letters to the editor (1997) (0)
Chapter 15 – Parkinsonism (2016) (0)
Multi‐infarct PSP (1987) (0)
Recent and Relevant (2011) (0)
Faculty Opinions recommendation of EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. (2019) (0)
Faculty Opinions recommendation of Emerging preclinical pharmacological targets for Parkinson's disease. (2016) (0)
Autoimmune movement disorders (2021) (0)
F1000Prime recommendation of Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. (2013) (0)
Faculty Opinions recommendation of Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson's disease. (2017) (0)
Faculty Opinions recommendation of Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? (2019) (0)
F1000Prime recommendation of One-year safety and tolerability profile of pridopidine in patients with Huntington disease. (2013) (0)
O.011 Psychogenic movement disorders (2009) (0)
Tratamiento del bruxismo grave mediante toxina botulínica. (2000) (0)
Unilateral Versus Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation for Axial Essential Tremor Symptoms (S18.003) (2018) (0)
Is Fixed Dystonia Always Psychogenic (2005) (0)
The Wide Spectrum of Functional Movement Disorders. (2019) (0)
TremAn: A Tool for Measuring Tremor Frequency from Video Sequences (2010) (0)
Balance Reaction in Healthy, Elderly Persons; Persons With Essential Tremor; and Persons With the Combination of Essential Tremor and Early-Stage Parkinsonʼs Disease (1996) (0)
Characterization of Tau Association with Parkinson's Disease (2003) (0)
Restless legs syndrome and cerebrovascular disease – Authors' reply (2013) (0)
Cervical dystonia patient registry for observation of onabotulinum /INS;toxin /INS;A efficacy (CD Probe): Pain at baseline (2013) (0)
Faculty Opinions recommendation of A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. (2014) (0)
Poster 89 Severity of Cervical Dystonia: Baseline Characteristics from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2012) (0)
Movement Disorders and Neuropsychiatric Conditions (2016) (0)
Letter to the editor (1997) (0)
Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors (2018) (0)
Genome-Wide Association Study of Gilles de la Tourette Syndrome (IN10-1.002) (2012) (0)
Faculty of 1000 evaluation for The relationship between glucocerebrosidase mutations and Parkinson disease. (2017) (0)
Faculty of 1000 evaluation for Targeted therapies for Parkinson's disease: From genetics to the clinic. (2018) (0)
Faculty Opinions recommendation of Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. (2016) (0)
Response to Shill and colleagues. (2016) (0)
Faculty Opinions recommendation of Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. (2019) (0)
Faculty Opinions recommendation of Diagnosis and treatment of parkinson disease: A review. (2020) (0)
Faculty Opinions recommendation of Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. (2016) (0)
Faculty Opinions recommendation of GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. (2017) (0)
Reply: Reflex sympathetic syndrome and peripheral dystonia (2003) (0)
F1000Prime recommendation of Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. (2013) (0)
Faculty Opinions recommendation of Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (2013) (0)
Faculty Opinions recommendation of Parkinsonism in essential tremor cases: A clinicopathological study. (2019) (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Study Design of a Prospective Observational Registry (2011) (0)
Faculty Opinions recommendation of A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. (2014) (0)
Toxins 2017 conference in Madrid. (2018) (0)
Hyperkinetic mutism (1987) (0)
Severity of Cervical Dystonia: Baseline Characteristics from the Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD-PROBE) (P01.231) (2012) (0)
Faculty Opinions recommendation of Amantadine in the treatment of Parkinson's disease and other movement disorders. (2021) (0)
Faculty Opinions recommendation of The gut and parkinson's disease: hype or hope? (2020) (0)
Table 2. [Differential Diagnosis for NKX2-1-Related Disorders]. (2016) (0)
Dystonia, Ataxia, Dementia, and a Family History of “Huntington Disease” (2012) (0)
Faculty Opinions recommendation of Parkin disease: a clinicopathologic entity? (2020) (0)
Current approaches to the treatment of Parkinsonrs disease (2008) (0)
Classification of Movement Disorders (2016) (0)
Baylor Functional Assessment Scale (2021) (0)
Faculty Opinions recommendation of Implications of the gut microbiome in parkinson's disease. (2020) (0)
Diagnostic Reliability of DaTscan in Movement Disorders (P03.125) (2012) (0)
Faculty Opinions recommendation of Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. (2014) (0)
Poster 135 Effectiveness and Safety in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2014) (0)
Special Issue: Toxins 2008: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins Foreword (2009) (0)
Alleviating Maneuvers (Sensory Tricks) in Cervical Dystonia (P2.046) (2014) (0)
Dystonic Respiratory Dysregulation and Other Breathing Disorders Associated with Dystonia (P01.223) (2012) (0)
Faculty Opinions recommendation of Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. (2018) (0)
Faculty Opinions recommendation of The neuropsychiatry of Parkinson's disease: advances and challenges. (2022) (0)
Reply (1999) (0)
Chapter 12 – Movement Disorders (2017) (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment Patterns and Subject Disposition (P7.062) (2014) (0)
Faculty Opinions recommendation of Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. (2018) (0)
Thermoregulatory dysfunction in Parkinson’s disease (2014) (0)
Notice of Redundant Publication: “Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease” (Arch Neurol. 2007;64[5]:676-682)—Reply (2007) (0)
Editorial: Neurotherapeutics of Movement Disorders (2013) (0)
Faculty Opinions recommendation of Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. (2017) (0)
Delineation of the Clinical Features and Treatment Response of Oromandibular Dystonia: A Multicenter Summary of 2,057 Cases. (2020) (0)
Faculty Opinions recommendation of The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease. (2020) (0)
Anti-GAD65 antibody-associated hemiataxia (2020) (0)
Movement disorders in systemic infections (2014) (0)
POST-TRAUMATIC MOVEMENT DISORDERS. AUTHOR'S REPLY (1995) (0)
Letters to the Editor Related to New Topics Implantation of the Nucleus Tegmenti Pedunculopontini in a PSP-P Patient: Safe Procedure, Modest Benefits (2009) (0)
50. Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxin A efficacy (CD PROBE) (2015) (0)
Faculty Opinions recommendation of Method to combat Parkinson's disease by astrocyte-to-neuron conversion. (2020) (0)
Tremblementessentiel et gne du rcepteur de la dopamine (2006) (0)
Faculty Opinions recommendation of Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. (2016) (0)
Faculty Opinions recommendation of Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. (2017) (0)
Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004) (2014) (0)
Editorial “Parkinsonism across the spectrum of movement disorders and beyond” (2021) (0)
Figure 1. [Phenotypic spectrum of NKX2-1-related disorders...]. (2016) (0)
Chapter 9 – Paroxysmal Dyskinesias (2016) (0)
Faculty of 1000 evaluation for The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. (2017) (0)
Faculty Opinions recommendation of ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease. (2021) (0)
Wilson disease (2021) (0)
Faculty of 1000 evaluation for International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. (2018) (0)
New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
Chapter 22 – Drug-Induced Movement Disorders in Children (2016) (0)
Faculty of 1000 evaluation for Parkinson's disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking. (2018) (0)
Tetrabenazine for Moderate vs. Severe/Disabling Chorea Associated with Huntington's Disease (HD) (P06.032) (2012) (0)
Botulinum toxin treatmentofcranial-cervical dystonia, spasmodic dysphonia, other focal dystonias andhemifacial spasm (1990) (0)
Editorial: Toxins 2017. (2016) (0)
Hereditary Spastic Paraplegia Due To A Novel Mutation in SPG11 Gene Presenting As Dopa Responsive Dystonia, Parkinsonism And Spasticity (P4.057) (2014) (0)
Faculty Opinions recommendation of Is acupuncture efficacious therapy in Parkinson's disease? (2014) (0)
Faculty Opinions recommendation of Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. (2015) (0)
Faculty Opinions recommendation of Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. (2014) (0)
How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson’s disease? (2023) (0)
Faculty Opinions recommendation of A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. (2016) (0)
Faculty Opinions recommendation of Validation of a prognostic index for Huntington's disease. (2016) (0)
Faculty Opinions recommendation of Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease. (2020) (0)
Faculty Opinions recommendation of Parkinson's disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. (2020) (0)
Chapter 5 – Motor Assessments (2016) (0)
Faculty Opinions recommendation of Targeting impulsivity in Parkinson's disease using atomoxetine. (2014) (0)
Faculty Opinions recommendation of Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. (2020) (0)
Migraine and Tourette Syndrome—Reply (2004) (0)
JANKOVIC, Joseph: Texas/USA (2019) (0)
ARISING Clinical evaluation of extracellular amino acids in severe head trauma by intracerebral in vivo microdialysis (0)
Faculty Opinions recommendation of New clinical trials for nonmotor manifestations of Parkinson's disease. (2015) (0)
THE ASSOCIATION OF PHYSICAL PERFORMANCE MEASURES WHILE ON AND OFF ANTIPARKINSONIAN MEDICATIONS.: 455 (1995) (0)
Faculty Opinions recommendation of Reversing a model of Parkinson's disease with in situ converted nigral neurons. (2020) (0)
Reply from the Author (1990) (0)
Levodopa-Induced Dyskinesias (2009) (0)
Emotion regulation and neuropsychological status in functional neurological disorder variants (0)
Negotiating Movement Disorders (2006) (0)
Faculty Opinions recommendation of Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease. (2019) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
EPIDEMIOLOGY AND PATHOGENESISIntroduction to Dystonia (2006) (0)
Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
Faculty Opinions recommendation of Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. (2020) (0)
Faculty Opinions recommendation of Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. (2017) (0)
Postural Stability in Early Parkinsonʼs Disease (1996) (0)
RETT'S SYNDROME. COMMENT. AUTHOR'S REPLY (1990) (0)
Faculty Opinions recommendation of Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. (2020) (0)
Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion (2021) (0)
Toxins 2017 conference in Madrid. (2018) (0)
Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity (2015) (0)
Faculty Opinions recommendation of Parkinson disease: Could gut microbiota influence severity of Parkinson disease? (2017) (0)
Faculty Opinions recommendation of GBA-Associated Parkinson's Disease and Other Synucleinopathies. (2020) (0)
Faculty of 1000 evaluation for VPS35, the retromer complex and parkinson's disease. (2017) (0)
Poster 279 Preliminary Baseline Data for Subjects with Blepharospasm From the XCiDaBLE Trial: A Phase IV, Prospective, Observational Study Evaluating IncobotulinumtoxinA (Xeomin®) for Cervical Dystonia or Blepharospasm (2012) (0)
Ask the Experts: Parkinson’s disease treatment pipelines (2013) (0)
Herpes zosterophthalmicus followed bycontralateral hemiparesis: reportoftwocasesandreview of literature (1985) (0)
Physiologic and Pathologic Tremors (2020) (0)
Reply to Gender Differences in Functional Movement Disorders: Sociocultural or Biological? (2020) (0)
Bradley - Neurology in Clinical Practice E-dition (Book + Website Package) 2 vols. (2007) (0)
Faculty Opinions recommendation of Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. (2020) (0)
Faculty Opinions recommendation of Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. (2020) (0)
Chapter 78 – Dyskinesias (2003) (0)
Repeated incobotulinumtoxinA injections with flexible dosing intervals in blepharospasm (2013) (0)

This paper list is powered by the following services:

Other Resources About Joseph Jankovic

en.wikipedia.org

What Schools Are Affiliated With Joseph Jankovic?

Joseph Jankovic is affiliated with the following schools:

Image Attributions

Image Source for Joseph Jankovic